PedAM
Pediatric Disease Annotations & Medicines
| Disease | ovarian cancer |
| Phenotype | C0238122|fallopian tube cancer |
| Sentences | 2 |
| PubMedID- 26244011 | At this time, melanoma and ovarian cancer (including fallopian tube cancer and primary peritoneal cancer) are the only solid tumors outside of the current indications in which nab-paclitaxel is an nccn-recommended treatment option.72,73 according to the nccn guidelines, nab-paclitaxel is listed as a category 2a recommendation for the treatment of advanced or metastatic melanoma, based on positive phase ii trial data in which nab-paclitaxel led to response rates of 22% to 26% in chemotherapy-naïve patients with metastatic melanoma.74,75 response rates have historically been <20% with commonly used cytotoxics including dacarbazine, temozolomide, and sb-paclitaxel with or without carboplatin.72 in a head-to-head phase iii trial of nab-paclitaxel 150 mg/m2 qw 3/4 vs dacarbazine 1,000 mg/m2 q3w for the treatment of chemotherapy-naïve patients, nab-paclitaxel led to a significant improvement in the primary endpoint of pfs (4.8 vs 2.5 months; hr 0.792; p=0.044) and a 2-month, nonsignificant improvement in os (12.6 vs 10.5 months; hr 0.897; p=0.271).76 neuropathy was a common grade ≥3 treatment-related event observed with nab-paclitaxel (25% vs 0% for dacarbazine); however, these events improved by ≥1 grade in a median of 28 days. |
| PubMedID- 25514761 | The 5-year disease-free survival rates were 100% in women with fallopian tube cancer and 93% in patients with epithelial ovarian cancer (p=.04). |
Page: 1